SEC Comment Letter for DermTech, Inc. (DMTKQ) (CIK 0001651944) — May 7, 2020
DermTech, Inc. (DMTKQ) (CIK 0001651944)
Date: May 7, 2020 · CIK: 0001651944 · Accession: 0000000000-20-003983
AI Filing Summary & Sentiment
File numbers found in text: 333-237991
Letter
United States securities and exchange commission logo May 6, 2020 John Dobak, M.D. Chief Executive Officer DermTech, Inc. 11099 N. Torrey Pines Road, Suite 100 La Jolla, CA 92037 Re:DermTech, Inc. Registration Statement on Form S-1 Filed May 4, 2020 File No. 333-237991 Dear Dr. Dobak: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Christian Hollweg, Esq.
Show Raw Text
United States securities and exchange commission logo
May 6, 2020
John Dobak, M.D.
Chief Executive Officer
DermTech, Inc.
11099 N. Torrey Pines Road, Suite 100
La Jolla, CA 92037
Re:DermTech, Inc.
Registration Statement on Form S-1
Filed May 4, 2020
File No. 333-237991
Dear Dr. Dobak:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Christian Hollweg, Esq.